BioReinno

BioReinno is a biotech company focused on driving the development of next-generation ADC drugs through the innovation of ADC underlying technologies. We have built four leading ADC technology platforms: chemical site-specific conjugation technology platform MCLICK, novel camptothecin LD platform with tunable release kinetics RACT, ultra-low DAR value ADC technology platform UDAC, and dual-payload ADC technology platform DPAC. The single or combined application of these innovative technologies can empower ADC innovation in at least the following aspects: the fine adjustment and uniformity improvement of ADC DAR value(DAR1/DAR2/DAR3/DAR4/DAR6), broadening the therapeutic window of camptothecin ADC, the development of ultra-low DAR value ADC and AOC, and the proportional adjustment and development of dual-payload ADC. We look forward to working with Biopharma, Biotech, CRO and CDMO around the world to accelerate the advancement of ADC drugs.